Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferasirox 5-Year Extension in Transfusion-Dependent Iron Overload
NCT01033747Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2003
- Primary completion
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of deferasirox in iron overload (2 arms), sponsored by Novartis. Primary endpoint: Relative Change From Baseline in Liver Iron Content (LIC) at 7 years. Started Feb 2003; status: completed.
02
Drugs
deferasirox
03
Conditions
iron overload
Beyond the preview
Go deeper on NCT01033747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01033747.